Search
BeiGene's "Zanubrutinib Tablets" Gain U.S. Marketing Approval
4 day ago /
Read about 0 minute
Author：小编
BeiGene's Zanubrutinib Tablets have secured marketing approval in the United States, expanding patient access to this medication in both capsule and tablet formulations. Zanubrutinib, an independently developed BTK inhibitor by BeiGene, first received U.S. approval in November 2019 in capsule form for the treatment of mantle cell lymphoma. To date, it boasts five approved indications. In 2024, global sales of Zanubrutinib capsules amounted to a substantial $2.644 billion.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
